Posts tagged GEN
Additional positive EarlyCDT-Lung data presented at ERS Congress, Milan

The National Health Service (NHS) Scotland-sponsored Early Cancer Detection Test – Lung Cancer Scotland (ECLS) study of 12,000 high-risk smokers has demonstrated additional, positive, early detection of lung cancer with the use of the EarlyCDT-Lung test.

Read More
GeneNews arranges up to $10-million financing with Milost

GeneNews (TSX:GEN) has signed a binding commitment letter with Milost Global, which will initially purchase up to $3-million in unsecured convertible notes from GeneNews, as part of an equity and debt subscription agreement of up to $10-million.

Read More
GeneNews launches risk stratification test for breast cancer

GeneNews (TSX:GEN) has launched BreastSentry, a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory (IDL).

Read More
GeneNews in pact with large physician group

GeneNews (TSX:GEN) has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests.

Read More
GeneNews introducing diagnostics to NueHealth physicians

GeneNews (TSX:GEN) has begun the process of introducing its portfolio of early cancer diagnostic tests to physicians in NeuHealth’s nationwide system of integrated physician networks (IPNs).

GeneNews’ partnership with NueHealth, announced in September 2016, is the first agreement from the company’s collaboration with JTS Health Partners (JTS).

Read More
GeneNews, NueHealth partner in early cancer diagnostics

GeneNews (TSX:GEN) has entered into a partnership agreement with closely-held NueHealth, which delivers value-based healthcare solutions and connects patients directly to physicians through integrated provider networks.

Patients who access healthcare through NueHealth's provider networks will now be able to take advantage of three different screening tests: ColonSentry, earlyCDT-Lung and Prostate Health Index, which provide early risk stratification of colorectal, lung and prostate cancers.

Read More
GeneNews closes private placement

GeneNews (TSX:GEN) has accepted subscriptions for a non-brokered private placement offering of 9,794,203 units, at a price of 16 cents each, for proceeds of about $1.6-million. 

Each unit consists of one common share and one-quarter of a warrant. Each whole warrant entitles the holder to acquire one common share at a price of 50 cents until August 15, 2018.

Read More
GeneNews resolves TSX, OSC issues

GeneNews (TSX:GEN), by raising additional financings via a series of transactions over the past few weeks, and filing its full year 2015 and 2016 first quarter results, has successfully resolved both the Toronto Stock Exchange continued listing review and the management cease trade order granted by the Ontario Securities Commission in March.

“The last six-to-12 months have been a challenging time for both the company and its shareholders,” executive chairman, James Howard-Tripp, said in a statement.

Read More
GeneNews closes note financing with Alumina

GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement.

Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 within the first 120 days. The 12% notes will have a term of one year.

Read More
GeneNews provides financing update

GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital.

The company also has executed a term sheet with Alumina Partners for a second tranche, allowing GeneNews to draw down on $10-million (US) in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period.

Read More
GeneNews arranging private placement

GeneNews (TSX:GEN) is undertaking a non-brokered private placement of up to 50 million common shares at a price of 10 cents apiece, or $5-million.

Any remaining unfunded portion of the offering may be raised with the issuance of a senior secured, collateralized convertible debenture. If needed, this convertible debenture would be issued with a term of one year, interest accrued and payable at 15% and with a conversion price of 16 cents a share.  The conversion would become mandatory if the common stock trades above 16 cents for 30 consecutive trading days.

Read More